Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx).

Celebrating the 10th anniversary of Advanced Science and the 5th anniversary of VIEW, the Advanced Science/VIEW Symposium: Advances in Biomedical Research And 2nd International Symposium on Materiobiology took place in Shanghai on 13-14 July 2024.

Diasorin (FTSE MIB: DIA) today announced that the Food and Drug Administration (FDA) has granted de-novo authorization for the Simplexa® C. auris Direct kit to test patients suspected of Candida auris colonization and aid in preventing potential spread in healthcare settings. This real-time polymerase chain reaction (RT-PCR) assay is used for the direct in vitro qualitative detection of C.auris DNA from a swab of axilla/groin from patients suspected of C. auris colonization, and detects the six C.auris clades that are circulating globally.

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year.

In 2019, the State Council successively promulgated three policy documents closely related to the biochemical analysis instruments and reagents, which laid an important policy foundation for the development of biochemical analysis instruments and reagents.

Oncocyte Corporation, a company specializing in in vitro and in vivo diagnostic substances, has regained compliance with Nasdaq's listing rules regarding board and audit committee composition. The notice of compliance was received by the company on Monday, following a period of noncompliance caused by the passing of director Alfred D. Kingsley on April 25, 2024.

Alzpath said Monday that it has signed a licensing agreement with Beckman Coulter Diagnostics for use of the Alzpath phosphorylated-tau 217 antibody in a blood-based test for Alzheimer's disease.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Laboratory Corporation of America on Thursday said it has entered into a comprehensive strategic collaboration with Florida's Naples Comprehensive Healthcare (NCH).

Element Biosciences said Thursday that it has raised more than $277 million in Series D funding.

To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing (NGS) technology, clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.

The World Health Organization announced Wednesday that it has prequalified an at-home, over-the-counter assay manufactured by OraSure Technologies for hepatitis C virus.

To support next-generation semiconductor and materials innovation, Thermo Fisher Scientific today announced the opening of its first electron microscopy demo center in Taiwan. This state-of-the-art facility, called a NanoPort, is strategically located in the region’s semiconductor manufacturing hub and designed to meet the area’s growing need for advanced analytical instruments and expertise. The new center is now one of six Thermo Fisher NanoPort facilities worldwide and will partner with semiconductor customers in the region.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, today announced a definitive agreement for Quest to acquire select assets of OhioHealth's outreach laboratory services business.

China's respiratory testing market shows significant growth potential, driven by increasing demand, technological advancements, supportive policies, and a growing market size.